[
  {
    "ts": null,
    "headline": "Here’s Why You Should Consider Selling Your Baxter (BAX) Shares",
    "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]",
    "url": "https://finnhub.io/api/news?id=d885b6fbd5e90c557b3ceeb07589a241bb977cd5c192f8a2d7ef55e4e42d8b8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755100759,
      "headline": "Here’s Why You Should Consider Selling Your Baxter (BAX) Shares",
      "id": 136340307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BAX",
      "source": "Yahoo",
      "summary": "Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]",
      "url": "https://finnhub.io/api/news?id=d885b6fbd5e90c557b3ceeb07589a241bb977cd5c192f8a2d7ef55e4e42d8b8c"
    }
  },
  {
    "ts": null,
    "headline": "BAX Q2 Deep Dive: Margin Pressure and Product Headwinds Temper Near-Term Outlook",
    "summary": "Healthcare company Baxter International (NYSE:BAX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter’s revenue guidance of $2.87 billion was less impressive, coming in 1% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 11.4% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=cd96f0a94d0b1382ec3c4889bd2a61ecad745b6e323411ba001641240f55701a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058058,
      "headline": "BAX Q2 Deep Dive: Margin Pressure and Product Headwinds Temper Near-Term Outlook",
      "id": 136328886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BAX",
      "source": "Yahoo",
      "summary": "Healthcare company Baxter International (NYSE:BAX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter’s revenue guidance of $2.87 billion was less impressive, coming in 1% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 11.4% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=cd96f0a94d0b1382ec3c4889bd2a61ecad745b6e323411ba001641240f55701a"
    }
  },
  {
    "ts": null,
    "headline": "Baxter’s Q2 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Baxter’s second quarter results were met with a significant negative market reaction following a combination of in-line sales and a notable shortfall in non-GAAP profit. Management attributed the mixed performance primarily to persistent hospital fluid conservation, modest demand in the Medical Products & Therapies and Pharmaceutical segments, and challenges related to product mix. COO Heather Knight highlighted the ongoing effects of lower U.S. patient admissions and evolving hospital protocols",
    "url": "https://finnhub.io/api/news?id=0960fab527c8609092b0aaa77a55e5d1d253599248cf4dd9f1f2d32f35e84106",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057934,
      "headline": "Baxter’s Q2 Earnings Call: Our Top 5 Analyst Questions",
      "id": 136328887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BAX",
      "source": "Yahoo",
      "summary": "Baxter’s second quarter results were met with a significant negative market reaction following a combination of in-line sales and a notable shortfall in non-GAAP profit. Management attributed the mixed performance primarily to persistent hospital fluid conservation, modest demand in the Medical Products & Therapies and Pharmaceutical segments, and challenges related to product mix. COO Heather Knight highlighted the ongoing effects of lower U.S. patient admissions and evolving hospital protocols",
      "url": "https://finnhub.io/api/news?id=0960fab527c8609092b0aaa77a55e5d1d253599248cf4dd9f1f2d32f35e84106"
    }
  }
]